Amy Schmotzer

560 total citations
16 papers, 456 citations indexed

About

Amy Schmotzer is a scholar working on Oncology, Hepatology and Surgery. According to data from OpenAlex, Amy Schmotzer has authored 16 papers receiving a total of 456 indexed citations (citations by other indexed papers that have themselves been cited), including 10 papers in Oncology, 5 papers in Hepatology and 4 papers in Surgery. Recurrent topics in Amy Schmotzer's work include Colorectal Cancer Treatments and Studies (9 papers), Cancer Treatment and Pharmacology (5 papers) and Pancreatic and Hepatic Oncology Research (4 papers). Amy Schmotzer is often cited by papers focused on Colorectal Cancer Treatments and Studies (9 papers), Cancer Treatment and Pharmacology (5 papers) and Pancreatic and Hepatic Oncology Research (4 papers). Amy Schmotzer collaborates with scholars based in United States. Amy Schmotzer's co-authors include Deborah A. Josbeno, Amit D. Tevar, Michael A. Dunn, Andrea F. DiMartini, Anthony Delitto, Douglas Landsittel, Ramesh K. Ramanathan, John McKolanis, Theresa L. Whiteside and Olivera J. Finn and has published in prestigious journals such as Journal of Clinical Oncology, The American Journal of Gastroenterology and Liver Transplantation.

In The Last Decade

Amy Schmotzer

16 papers receiving 452 citations

Peers

Amy Schmotzer

ONCOL

PHYSI

HEPAT

IMMUN

SURGE

Marc Hilmi France

Yan‐Fang Xing China

Simon Johannes Gairing Germany

Fatih Saygılı Türkiye

Yifei Tan China

Ryoga Hamura Japan

Hui-Min Yan China

Masatsugu Ohara Japan

Mohamed Ramdani France

Faïza Khemissa France

Marc Hilmi France

Amy Schmotzer

421 ×2.0

ONCOL

103 ×0.6

PHYSI

63 ×0.5

HEPAT

115 ×0.9

IMMUN

128 ×1.5

SURGE

Citations per year, relative to Amy Schmotzer Amy Schmotzer (= 1×) peers Marc Hilmi

Countries citing papers authored by Amy Schmotzer

Since Specialization

Citations

This map shows the geographic impact of Amy Schmotzer's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Amy Schmotzer with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Amy Schmotzer more than expected).

Fields of papers citing papers by Amy Schmotzer

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Amy Schmotzer. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Amy Schmotzer. The network helps show where Amy Schmotzer may publish in the future.

Co-authorship network of co-authors of Amy Schmotzer

This figure shows the co-authorship network connecting the top 25 collaborators of Amy Schmotzer. A scholar is included among the top collaborators of Amy Schmotzer based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Amy Schmotzer. Amy Schmotzer is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

16 of 16 papers shown

1.

Josbeno, Deborah A., Amy Schmotzer, Christopher B. Hughes, et al.. (2019). Gait Speed and Grip Strength Are Associated With Dropping Out of the Liver Transplant Waiting List. Transplantation Proceedings. 51(3). 794–797. 21 indexed citations

2.

Dunn, Michael A., Deborah A. Josbeno, Amit D. Tevar, et al.. (2016). Frailty as Tested by Gait Speed is an Independent Risk Factor for Cirrhosis Complications that Require Hospitalization. The American Journal of Gastroenterology. 111(12). 1768–1775. 109 indexed citations

3.

Dunn, Michael A., Deborah A. Josbeno, Amy Schmotzer, et al.. (2016). The gap between clinically assessed physical performance and objective physical activity in liver transplant candidates. Liver Transplantation. 22(10). 1324–1332. 69 indexed citations

4.

Yang, Zhineng J., et al.. (2015). Plasma from chronic liver disease subjects exhibit differential ability to generate thrombin. Blood Coagulation & Fibrinolysis. 26(7). 844–847. 2 indexed citations

5.

Sehgal, Rajesh, Barry C. Lembersky, Edward P. Balaban, et al.. (2011). A Phase I/II Study of Capecitabine Given on a Week on/Week off Schedule Combined With Bevacizumab and Oxaliplatin for Patients With Untreated Advanced Colorectal Cancer. Clinical Colorectal Cancer. 10(2). 117–120. 3 indexed citations

6.

Carneiro, Benedito A., Ramesh K. Ramanathan, Marwan Fakih, et al.. (2011). Phase II Study of Irinotecan and Cetuximab Given Every 2 Weeks as Second-Line Therapy for Advanced Colorectal Cancer. Clinical Colorectal Cancer. 11(1). 53–59. 13 indexed citations

7.

Lo, Shelly S., Alok A. Khorana, Milind Javle, et al.. (2010). A Phase II Study of Weekly Docetaxel in Combination with Capecitabine in Advanced Gastric and Gastroesophageal Adenocarcinomas. Oncology. 78(2). 125–129. 18 indexed citations

8.

Brell, Joanna M., Khalid Matin, Terry Evans, et al.. (2009). Phase II Study of Docetaxel and Gefitinib as Second-Line Therapy in Gemcitabine Pretreated Patients with Advanced Pancreatic Cancer. Oncology. 76(4). 270–274. 29 indexed citations

9.

Ramanathan, Ramesh K., Marwan Fakih, Smitha Krishnamurthi, et al.. (2008). Phase II study of irinotecan (I) and cetuximab (C) on an every 2 week schedule, as second line therapy in patients (pts) with advanced colo-rectal cancer (CRC). Journal of Clinical Oncology. 26(15_suppl). 15050–15050. 1 indexed citations

10.

Lepisto, Andrew J., A. James Moser, Herbert J. Zeh, et al.. (2008). A phase I/II study of a MUC1 peptide pulsed autologous dendritic cell vaccine as adjuvant therapy in patients with resected pancreatic and biliary tumors.. PubMed. 6(B). 955–964. 161 indexed citations

11.

Ramanathan, Ramesh K., Edward P. Balaban, Patrick M. Kane, et al.. (2007). Phase II study of the A-ICOX regimen [bevacizumab (Bev), weekly intermittent capecitabine (Cap) and oxaliplatin (Ox)] for untreated advanced colorectal cancer (CRC). Journal of Clinical Oncology. 25(18_suppl). 4092–4092. 1 indexed citations

12.

Brell, Joanna M., Khalid Matin, Terry Evans, et al.. (2007). Phase II study of gefitinib and docetaxel for patients (pts) with advanced pancreatic adenocarcinoma (APC) progressing after first-line therapy. Final results. Journal of Clinical Oncology. 25(18_suppl). 4586–4586. 2 indexed citations

13.

Patel, Hitendra, Ronald G. Stoller, Miklos Auber, et al.. (2006). Phase II study of rubitecan, an oral camptothecin in patients with advanced colorectal cancer who have failed previous 5-fluorouracil based chemotherapy. Investigational New Drugs. 24(4). 359–363. 10 indexed citations

14.

Matin, Khalid, Terry Evans, James J. Schlesselman, et al.. (2006). Phase II study of gefitinib and docetaxel as salvage therapy in patients (pts) with advanced pancreatic adenocarcinoma (APC). Journal of Clinical Oncology. 24(18_suppl). 4120–4120. 6 indexed citations

15.

Finn, Olivera J., Theresa L. Whiteside, John McKolanis, et al.. (2004). A phase 1B study of a MUC1 pulsed autologous dendritic cell (DC) vaccine as adjuvant therapy in patients (Pts) with resected pancreatic or biliary tumors. Journal of Clinical Oncology. 22(14_suppl). 2578–2578. 7 indexed citations

16.

Finn, Olivera J., Theresa L. Whiteside, John McKolanis, et al.. (2004). A phase 1B study of a MUC1 pulsed autologous dendritic cell (DC) vaccine as adjuvant therapy in patients (Pts) with resected pancreatic or biliary tumors. Journal of Clinical Oncology. 22(14_suppl). 2578–2578. 4 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact